Drug Profile


Alternative Names: amlodipine/HCTZ/losartan; amlodipine/losartan/hydrochlorothiazide; hydrochlorothiazide/amlodipine/losartan; losartan/amlodipine/hydrochlorothiazide; MK-0954E

Latest Information Update: 03 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antihypertensives; Benzothiadiazines; Biphenyl compounds; Dihydropyridines; Heart failure therapies; Imidazoles; Ischaemic heart disorder therapies; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Thiazide diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Hypertension

Most Recent Events

  • 03 Aug 2015 No recent reports on development identified - Phase-III for Hypertension in Japan (PO)
  • 26 Apr 2012 Merck completes a phase III trial in Hypertension in Japan (NCT01302691)
  • 12 Jan 2012 Merck completes enrolment in its phase III trial for Hypertension in Japan (NCT01302691)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top